Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival (vol 11, pg 21, 2010)

被引：0

|

作者：

Bonner, J. A.

Harari, P. M.

Giralt, J.

机构：

来源：

LANCET ONCOLOGY | 2010年 / 11卷 / 01期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

收藏

页码：14 / 14

页数：1

相关论文

共 6 条

[1] Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
Bonner, James A.
Harari, Paul M.
Giralt, Jordi
Cohen, Roger B.
Jones, Christopher U.
Sur, Ranjan K.
Raben, David
Baselga, Jose
Spencer, Sharon A.
Zhu, Junming
Youssoufian, Hagop
Rowinsky, Eric K.
Ang, K. Kian
LANCET ONCOLOGY, 2010, 11 (01): : 21 - 28
[2] Phase II-trial of concomitant hyperfractionated-accelerated radiotherapy (HART) with cisplatin (Cis) plus cetuximab (Cet) for locoregionally advanced inoperable squamous cell head and neck cancer: 5-year end results
Kuhnt, T.
Schreiber, A.
Pirnasch, A.
Hautmann, M. G.
Hass, P.
Sieker, F. P.
Engenhart-Cabilic, R.
Richter, M.
Dellas, K.
Dunst, J.
ANNALS OF ONCOLOGY, 2016, 27
[3] Long-Term Update of NRG/RTOG 0522: A Randomized Phase 3 Trial of Concurrent Radiation and Cisplatin With or Without Cetuximab in Locoregionally Advanced Head and Neck Cancer (vol 116, pg 533, 2023)
Caudell, Jj
Torres-Saavedra, Pa
Rosenthal, Di
Axelrod, Rs
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (03): : 774 - 776
[4] Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial (vol 383, pg 603, 2014)
Vaidya, J. S.
Wenz, F.
Bulsara, M.
LANCET, 2014, 383 (9917): : 602 - 602
[5] Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial (vol 18, pg 732, 2017)
Dieras, V
Miles, D.
Verma, S.
LANCET ONCOLOGY, 2018, 19 (12): : E667 - E667
[6] Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial (vol 18, pg 732, 2017)
Dieras, V
Miles, D.
Verma, S.
LANCET ONCOLOGY, 2017, 18 (08): : E433 - E433